Heyuan Biotech announced that the company reviewed and passed a bill to postpone some fund-raising projects, and adjusted the time for the initial public offering of shares, the “Recombinant Human Albumin Industrialization Base Construction Project” to reach the scheduled state of use from September 2026 to June 2027. The total investment of the project was 1,909 billion yuan, and the capital raised was promised to invest 1,658 million yuan. As of August 21, 2026, the total investment was 892 million yuan, and the investment progress was 53.84%. This extension does not involve changes in the subject, method, or scale of investment of the project. There is no change in the direction of capital raised, there is no need to submit it to the shareholders' meeting for review, and the sponsor agency has issued an unobjected verification opinion.

Heyuan Biotech announced that the company reviewed and passed a bill to postpone some fund-raising projects, and adjusted the time for the initial public offering of shares, the “Recombinant Human Albumin Industrialization Base Construction Project” to reach the scheduled state of use from September 2026 to June 2027. The total investment of the project was 1,909 billion yuan, and the capital raised was promised to invest 1,658 million yuan. As of August 21, 2026, the total investment was 892 million yuan, and the investment progress was 53.84%. This extension does not involve changes in the subject, method, or scale of investment of the project. There is no change in the direction of capital raised, there is no need to submit it to the shareholders' meeting for review, and the sponsor agency has issued an unobjected verification opinion.